Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that nine-month Phase II and combined Phase I and Phase II data on the NSI-566 trial in amyotrophic lateral sclerosis (ALS) was presented at the American Neurological Association Annual Meeting by principal investigator, Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health.  The data showed that the intraspinal transplantation of the cells was safe and well-tolerated throughout the escalating doses, reaching a maximum tolerated dose of 16 million cells via 20 bilateral injections.  There appeared to be no acceleration in disease progression due to the therapeutic intervention.

Researchers calculated a 95% confidence limit around the slopes of decline of ALSFRSr scores, forced vital capacity (FVC) and grip strength of the ProAct historical database subjects, and evaluated if trial subjects fell within or outside those limits. 73% of Phase II patients, and 79% of combined Phase I and II patients, fell above the upper confidence limit of the ALSFRSr score. 50% of Phase I and II combined, and 40% of Phase II patients’ forced vital capacity percent predicted fell above the upper confidence limit, compared to the ProAct database.  ALSFRSr scores correlated most strongly with FVC preservation, which was the target of the cervical injections.   For grip strength control, researchers used the Ceftriaxone (CEF) study database, since grip strength data was not available in the ProAct database.  67% of Phase I and II combined, and 60% of Phase II patients, all at nine months post-intervention, fell above the 95% upper confidence limit.

The most common adverse event (AE) was transient post-operative pain due to surgery.  One serious adverse event due to the surgical procedure was observed, but was not attributed to the cells themselves. The patient’s motor function was initially weakened and then recovered to the patient’s ALS baseline.

“Based on this encouraging safety and clinical effect,  we look forward to moving to a  registration-directed trial in 2016,” said Karl Johe, PhD, Chief Scientific Officer. (Original Source)

Shares of Neuralstem closed yesterday at $1.58. CUR has a 1-year high of $3.92 and a 1-year low of $1.25. The stock’s 50-day moving average is $1.47 and its 200-day moving average is $1.77.

On the ratings front, Neuralstem has been the subject of a number of recent research reports. In a report issued on August 10, Brean Murray Carret analyst Jonathan Aschoff maintained a Buy rating on CUR, with a price target of $8, which implies an upside of 406.3% from current levels. Separately, on June 29, Rodman & Renshaw’s Ram Selvaraju reiterated a Buy rating on the stock and has a price target of $6.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jonathan Aschoff and Ram Selvaraju have a total average return of -5.4% and 3.8% respectively. Aschoff has a success rate of 35.3% and is ranked #3607 out of 3752 analysts, while Selvaraju has a success rate of 42.6% and is ranked #914.

Neuralstem Inc is a biotechnology company. It is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs.